Skip to main content

Motif Bio

Motif Bio plc
One Tudor Street
London, EC4Y 0AH
United Kingdom
In June 2021, Motif Bio plc announced at its general meeting that several resolutions for the the proposed acquisition of BiVictriX Therapeutics were not passed, and as such the company would be cancelled from trading. Shares of Motif Bio PLC were suspended from trading in July 2021.

Motif Bio plc was a clinical-stage biopharmaceutical company focused on developing novel antibiotics. The company’s lead product candidate was iclaprim, an investigational broad-spectrum diaminopyrimidine antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The U.S. FDA issued a Complete Response Letter (CRL) in 2019 regarding the New Drug Application (NDA) for iclaprim stating that that additional data were needed to further evaluate the risk for liver toxicity. The failure to gain FDA approval for the drug resulted in the eventual demise of the company.

Latest news